NFE2L2 and thyroid gland carcinoma: These data indicate that the mechanisms by which Nrf2 promotes resistance to proteasome inhibitors in thyroid cancer are not limited to interactions with regulators of apoptosis (ATF4, ORP150, and CHOP), but also include the direct modulation of the cells' redox status.